- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07930559
Effect of S-Ibuprofen Gel on Pain in Acute Soft Tissue Contusions
Randomized, Controlled, Multi-center Trial to Evaluate the Efficacy, Tolerability, and Safety of an S-Ibuprofen Gel vs. Placebo in the Local Symptomatic and Short-Term Treatment of Pain in Acute Contusions of the Soft Tissues Following Blunt Trauma
Phase 3 study designed to evaluated analgesic efficacy and safety of S-Ibuprofen Topical Gel 5%
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The purpose of this randomized, double-blind study is to evaluate the efficacy and safety of S-Ibuprofen Topical Gel 5% in treatment of pain in acute contusions of the soft tissues following blunt trauma.
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Bonn, Allemagne, 53113
- Recrutement
- Dr. med Jürgen Ulrich Schaale-Maas
-
Contact:
- Jurgen Schaale-Maas, Dr.med.
- Numéro de téléphone: +49 177 7373443
- E-mail: jschaale@icloud.com
-
Bonn, Allemagne, 53121
- Recrutement
- Orthopädische Praxis-Ebert
-
Contact:
- Eduart Ebert, Dr. med.
- Numéro de téléphone: +49 173 7038059
- E-mail: ebert.e@web.de
-
Gilching, Allemagne, 82205
- Recrutement
- Dr. Helmut Pabst
-
Contact:
- Helmut Pabst, Dr
- Numéro de téléphone: +49 814 123026
- E-mail: h.pabst@pwc-gmbh.de
-
-
-
-
Oregon
-
Bend, Oregon, États-Unis, 97702
- Recrutement
- Northwest Foot Care - Amanda Westfall McCarty
-
Contact:
- Amanda Westfall McCarty, DPM
- Numéro de téléphone: 541-385-7129
- E-mail: amanda@nwfootcarebend.com
-
Bend, Oregon, États-Unis, 97702
- Recrutement
- Northwest Foot Care - Bryan Wilhelm
-
Contact:
- Bryan Wilhelm, DPM
- Numéro de téléphone: 541-385-7129
- E-mail: bwilh29@gmail.com
-
Bend, Oregon, États-Unis, 97702
- Recrutement
- Northwest Foot Care - Hayden Bush
-
Contact:
- Hayden Bush, DPM
- Numéro de téléphone: 435-655-5127
- E-mail: haydenbush91@gmail.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Acute soft-tissue injury/contusion.
- Enrollment within 6 hours of the injury.
- Baseline NRS score for POM of injured location >5 score points on an 11-point NRS.
- Size of injury, as assessed by the investigator, ≥25 cm2 and ≤120 cm2
- Adult male or female patients aged ≥18 years.
- Having given written informed consent.
- Satisfactory health as determined by the investigator based on medical history and physical examination.
Exclusion Criteria:
- Significant concomitant injury in association with the acute injury; e.g., fracture, nerve injury, ligament disruption, tear of muscle or cartilage, or open wound.
- Excessively hairy skin at application site, cutting the hair in the injured site prior to gel application will qualify for inclusion.
- Current skin disorder or shaving hair at application site.
- History of excessive sweating/hyperhidrosis inclusive of application site.
- Treatment with topical or systemic NSAIDs or analgesics within 36 hours, opioids within 7 days, or corticosteroids within 60 days of inclusion in the study.
- Intake of long-acting NSAIDs or application of topical medication since the injury (rest-ice-compression-elevation [RICE] is allowed).
- Participation in a clinical study within 30 days before inclusion in the study or concomitantly.
- Positive drug or alcohol screen or evidence of drug or alcohol abuse in the opinion of the investigator.
- Pregnant or lactating or intending to become pregnant during the study.
- Individuals of reproductive potential who do not agree to use of an acceptable birth control method throughout the study, when engaging in any sexual activity that comes with a risk of pregnancy.
- History of any allergy or hypersensitivity (e.g., anaphylaxis, urticaria/hives, rhinitis, skin reaction, asthma, angioedema, or other allergic symptoms) to acetaminophen, ibuprofen, other NSAIDs, or to 1 of the excipients of the gel.
- History of severe cutaneous adverse reactions to any medication, such as Stevens-Johnson syndrome (SJS), erythema multiforme, toxic epidermal necrolysis (TEN), or acute generalized exanthematous pustulosis.
- Any ongoing condition that may interfere with the absorption, distribution, metabolism, or excretion of S-ibuprofen gel 5%.
- History of previous significant injury to the same extremity within 6 months.
- Patients with a disease affecting the same area, such as synovitis, rheumatoid arthritis, arthrosis, etc.
- Patients experiencing symptoms of an infectious disease including swelling of any joint of the affected area.
- Patients having an ongoing painful condition associated with the injury/contusion.
- Patients who had surgery of the affected area within 1 year of study entry.
- Patients with significant diseases (defined as a disease which, in the opinion of the investigator, may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study; including patients with a history of gastrointestinal bleeding, significant cardiovascular, liver, or renal disease).
- Patients with a blood coagulation disorder.
- Patients who use any impermissible medication (eg. systemic or topical NSAIDs, analgesics (other than paracetamol), opiods, corticosteroids (except for topical treatment of bronchial asthma, heparin, or psychotropic agents)
- Patients who participated in previous clinical studies of S-ibuprofen gel 5% and patients of the same household.
- Patients who are related to those persons involved directly or indirectly with the conduct of the study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: S-Ibuprofen Topical Gel 5%
S-Ibuprofen Topical Gel 5% applied once per day to the affected injury site |
Topical gel containing active ingredient S-ibuprofen |
|
Comparateur placebo: Vehicle Topical Gel
Placebo Gel applied once per day to the affected injury site |
Placebo gel matching the active comparator in conposition and appearance without the active ingredient |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Evaluation of the efficacy of S-ibuprofen gel 5% applied once every 24 hours compared with placebo in patients with acute contusions of the soft tissues following blunt trauma
Délai: 0-24 hours
|
Change from baseline/pain intensity difference of numerical rating scale (NRS) scores for pain-on-movement at 24 hours. NRS scale 0-10, 0=no pain, 10=worst possible pain. |
0-24 hours
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Time to first perceptible pain relief based on direct questions to the patient and what they consider perceptible pain relief
Délai: From time 0 every 24 hours up to 7 days
|
Recorded as time in minutes. Optional use of NRS scale. NRS scale 0-10, 0=no pain, 10=worst possible pain. |
From time 0 every 24 hours up to 7 days
|
|
Time to onset of meaningful pain relief based on direct questions to the patient and what they consider meaningful pain relief
Délai: From time 0 to end of study (day 7)
|
Recorded as time in minutes. Optional use of NRS scale. NRS scale 0-10, 0=no pain, 10=worst possible pain. |
From time 0 to end of study (day 7)
|
|
Time gap between first perceptible pain relief and meaningful pain relief based on direct questions to the patient
Délai: From time 0 to end of study (day 7)
|
Calculated as a difference to reach perceptible vs meaningul pain relief. |
From time 0 to end of study (day 7)
|
|
Change from baseline/pain intensity difference of numerical rating scale (NRS) scores for spontaneous pain-on-movement (sPOM) at 24 hours
Délai: At 24 hours
|
Recorded in patient diary based on NRS scores for sPOM at 24 hours. NRS scale 0-10, 0=no pain, 10=worst possible pain. |
At 24 hours
|
|
Change from baseline for pain-at-rest (PAR) measured by numerical rating scale (NRS) at Visit 2, Visit 3, Visit 4, Visit 5, Visit 6
Délai: At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
|
Based on NRS scores for PAR at 24 hours. NRS scale 0-10, 0=no pain, 10=worst possible pain. |
At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
|
|
Change from baseline for pain-on-movement (POM) measured at Visit 3, Visit 4, Visit 5, and Visit 6
Délai: At Visit 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
|
Based on NRS scores for POM. NRS scale 0-10, 0=no pain, 10=worst possible pain. |
At Visit 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
|
|
Change from baseline for spontaneous pain-on-movement measured at 6 (±2), 8 (±2), 12 (±2), 16 (±2), 24 (±4), 36 (±4), 48 (±4), 60 (±4), 72 (±4), 84 (±4), 96 (±4), 120 (±4), 144 (±4), and 168 (±24) hours
Délai: 6 (±2), 8 (±2), 12 (±2), 16 (±2), 24 (±4), 36 (±4), 48 (±4), 60 (±4), 72 (±4), 84 (±4), 96 (±4), 120 (±4), 144 (±4), and 168 (±24) hours after initial treatment administration
|
When possible, recorded in patient diary. NRS scale 0-10, 0=no pain, 10=worst possible pain. |
6 (±2), 8 (±2), 12 (±2), 16 (±2), 24 (±4), 36 (±4), 48 (±4), 60 (±4), 72 (±4), 84 (±4), 96 (±4), 120 (±4), 144 (±4), and 168 (±24) hours after initial treatment administration
|
|
Pain-on-movement at the injured site recorded on a numerical rating scale (NRS) scale in the presence of the investigator for the timepoints at Visit 2, Visit 3, Visit 4, Visit 5, and Visit 6
Délai: At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
|
NRS scale 0-10, 0=no pain, 10=worst possible pain. |
At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
|
|
Sum of pain intensity differences (SPIDs) for pain-on-movement at Visit 2, Visit 3, Visit 4, Visit 5, and Visit 6
Délai: At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
|
NRS scale 0-10, 0=no pain, 10=worst possible pain. |
At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
|
|
Baseline-adjusted area under the curve (AUC) for pain-on-movement at the injured site recorded on a numerical rating scale (NRS) in the presence of the investigator for the timepoints at Visit 2, Visit 3, Visit 4, Visit 5, and Visit 6
Délai: At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
|
NRS scale 0-10, 0=no pain, 10=worst possible pain. |
At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
|
|
Pain at rest measured by a numerical rating scale (NRS) at baseline at Visit 2, Visit 3, Visit 4, Visit 5, and Visit 6
Délai: At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
|
NRS scale 0-10, 0=no pain, 10=worst possible pain. |
At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
|
|
Time-specific pain intensity difference for spontaneous pain-on-movement at all time points
Délai: Time 0 to end of study (day 7)
|
Recorded in patient diary. Calculated from NRS scale data generated throughout the study. NRS scale 0-10, 0=no pain, 10=worst possible pain. |
Time 0 to end of study (day 7)
|
|
Time-specific pain intensity difference for pain at rest at all time points
Délai: Time 0 to end of study (day 7)
|
Recorded in patient diary. Calculated from NRS scale data generated throughout the study.NRS scale 0-10, 0=no pain, 10=worst possible pain. |
Time 0 to end of study (day 7)
|
|
Time-specific pain intensity difference for spontaneous pain on movement at all time points
Délai: Time 0 to end of study (day 7)
|
Recorded in patient diary. Calculated from NRS scale data generated throughout the study. NRS scale 0-10, 0=no pain, 10=worst possible pain. |
Time 0 to end of study (day 7)
|
|
Time-specific pain intensity difference for pain at rest at all time points
Délai: Time 0 to end of study (day 7)
|
Recorded in patient diary. Calculated from NRS scale data generated throughout the study. NRS scale 0-10, 0=no pain, 10=worst possible pain. |
Time 0 to end of study (day 7)
|
|
Time to complete pain relief (Score = 0 pain)
Délai: Time 0 to end of study (day 7)
|
NRS scale 0-10, 0=no pain, 10=worst possible pain. |
Time 0 to end of study (day 7)
|
|
Time to complete resolution of pain-on-movement (Score = 0 pain)
Délai: Time 0 to end of study (day 7)
|
NRS scale 0-10, 0=no pain, 10=worst possible pain. |
Time 0 to end of study (day 7)
|
|
Time to complete resolution of pain at rest (Score = 0 of pain)
Délai: Time 0 to end of study (day 7)
|
NRS scale 0-10, 0=no pain, 10=worst possible pain. |
Time 0 to end of study (day 7)
|
|
Time to the first request of rescue medication within the first 24 hours
Délai: Time 0 to 24 hours
|
If applicable |
Time 0 to 24 hours
|
|
Proportion of patients taking rescue medication per dosing interval and during the entire evaluation period
Délai: Time 0 to end of study (day 7)
|
If applicable |
Time 0 to end of study (day 7)
|
|
Responder rate (defined as the number of patients achieving 50% reduction from baseline in the NRS score for pain-on-movement at 24 hours)
Délai: Time 0 to 24 hours
|
NRS scale 0-10, 0=no pain, 10=worst possible pain. |
Time 0 to 24 hours
|
|
Global efficacy assessment by investigator (5 point scale) at Visit 2, Visit 3, Visit 4, and Visit 6
Délai: At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), and 6 (~168 hours)
|
5-point Likert scale. 0 = excellent, 4 = very poor |
At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), and 6 (~168 hours)
|
|
Global efficacy assessments by patient (5 point scale) at Visit 2, Visit 3, Visit 4, and Visit 6
Délai: At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), and 6 (~168 hours)
|
5-point Likert scale. 0 = excellent, 4 = very poor |
At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), and 6 (~168 hours)
|
|
Overall dose of rescue medication
Délai: Time 0 to end of study (Day 7)
|
Rescue medication use will be assessed at every visit except Visit 1 |
Time 0 to end of study (Day 7)
|
|
Local tolerability at every visit except V1
Délai: Time 0 to end of study (day 7)
|
Examination for presence of erythema (0-3, 0 = none; 3 = severe), edema (0-3, 0 = none; 3 = severe), papiculation/vesiculation (0-3, 0 = none; 3 = severe), pruritus (NRS scale 0-10; 0 = no itch, 10 = worst possible itch), burning (NRS scale 0-10; 0 = no itch, 10 = worst possible itch) |
Time 0 to end of study (day 7)
|
|
Blood pressure exam at V1 and V6
Délai: At Visit 1 (time 0) and 6 (168 hours)
|
Systolic/diastolic blood pressure |
At Visit 1 (time 0) and 6 (168 hours)
|
|
Adverse events at every visit
Délai: Time 0 to end of study (day 7)
|
Time 0 to end of study (day 7)
|
|
|
Examination of pulse at V1 and V6
Délai: At Visit 1 (time 0) and 6 (168 hours)
|
Pulse measured as beats per minute |
At Visit 1 (time 0) and 6 (168 hours)
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- AP-009
- 2025 (Subvention/contrat des NIH des États-Unis)
- 2025-524451-31-00 (Ctis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .